New York Times CENTER-LEFT (-1.0) Reliability: 8.0/10

Opinion | Do you take a GLP-1 for alternative uses? Tell us about it.

✍️ New York Times Opinion 📅 November 09, 2025 12:00 AM 🕐 Scraped: November 09, 2025

Summary: Some semaglutide users experience benefits beyond weight loss. Are you one of them?

Drugs like Ozempic, known collectively as GLP-1 receptor agonists, have become more widely used in recent

📰

Continue Reading on New York Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

New York Times Opinion

Original Publisher

🌍 New York Times

CENTER-LEFT Bias (-1.0)

Published Date

November 09, 2025 at 12:00 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.

Desktop Only